PMC:7200337 / 32773-32943
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T334 | 120-131 | Body_part | denotes | lymphocytes | http://purl.org/sig/ont/fma/fma62863 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T151 | 35-37 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T153 | 49-59 | Chemical | denotes | antagonist | http://purl.obolibrary.org/obo/CHEBI_48706 |
| T154 | 60-71 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1071 | 82-84 | Gene | denotes | to | Gene:6999 |
| 1083 | 60-71 | Chemical | denotes | tocilizumab | MESH:C502936 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T183 | 0-170 | Sentence | denotes | In support of this hypothesis, the IL-6 receptor antagonist tocilizumab was found to increase the number of circulating lymphocytes (Giamarellos-Bourboulis et al., 2020). |